Skip Navigation

European Heart Journal 2001 22(4):294-299; doi:10.1053/euhj.2000.2239
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kluijtmans, L.A.J
Right arrow Articles by Whitehead, A.S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kluijtmans, L.A.J
Right arrow Articles by Whitehead, A.S
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Methylenetetrahydrofolate reductase genotypes and predisposition to atherothrombotic disease. Evidence that all three MTHFR C677T genotypes confer different levels of risk

L.A.J Kluijtmansf2 and A.S Whiteheadf1

Department of Pharmacology and Center for Pharmacogenetics, University of Pennsylvania School of Medicine, Philadelphia, PA, U.S.A.

Abstract

Aims Elevated plasma homocysteine is an independent risk factor for atherothrombotic disease. Individuals homozygous for the methylenetetrahydrofolate reductase (MTHFR) 677C allele exclusively accumulate 5methyltetrahydrofolate, the methyl donor for homocysteine remethylation, in their red blood cells; this contrasts with 677 TT homozygotes who also accumulate significant levels of non-methylated folate derivatives. Those with the MTHFR 677 TT, CT and CC genotypes may therefore differ qualitatively with respect to folate utilization and hence their capacity to remethylate homocysteine. This study was consequently designed to establish whether all three genotypes confer different levels of atherothrombotic risk.

Methods and Results The risk of atherothrombotic disease conferred by the MTHFR 677 CT and 677 CC genotypes was assessed using a ‘restricted’ meta-analysis approach applied to subjects from the first ten studies reporting a significantly increased risk conferred by the 677 TT genotype. The defined risk of the TT genotype in each of these ten studies was judged by us to denote ‘genetic vulnerability’ in the populations from which subjects were drawn. After proportional adjustment for the greater number of case TT homozygotes, the CT and CC frequencies observed in cases were compared with expectations based on the frequencies of these genotypes in controls. The observed CT frequency among cases was higher than expected in eight of the ten studies. In the meta-analysis, which included 1857 cases and 2942 controls, 847 (45·6%) cases, instead of the 777 (41·8%) expected, had the MTHFR CT genotype (P=0·010).

Conclusions Our findings suggest that the three MTHFR C677T genotypes confer different levels of atherothrombotic risk in ‘genetically vulnerable’ populations: CT heterozygotes have an elevated risk over CC homozygotes. One explanation is that the CT genotype actively confers atherothrombotic risk. An alternative interpretation however, for which a biologically plausible mechanism is proposed, is that CC is a protective genotype.

Key Words: Methylenetetrahydrofolate reductase polymorphism, atherothrombotic risk, folate derivatives, homocysteine, heterozygote risk

f2 Current address: Department of Pediatrics, University Medical Center, St. Radbood, Nijmegen, The Netherlands.

f1 Correspondence: Dr A. S. Whitehead, Department of Pharmacology, University of Pennsylvania School of Medicine, 153 Johnson Pavilion, 3620 Hamilton Walk, Philadelphia, PA 19104-6084, U.S.A.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Med. Genet.Home page
O Goker-Alpan, R Schiffmann, M E LaMarca, R L Nussbaum, A McInerney-Leo, and E Sidransky
Parkinsonism among Gaucher disease carriers
J. Med. Genet., December 1, 2004; 41(12): 937 - 940.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. Bauriedel, A. Jabs, D. Skowasch, R. Hutter, J. J. Badimon, V. Fuster, U. Welsch, and B. Luderitz
Dendritic cells in neointima formation after rat carotid balloon injury: coordinated expression withanti-apoptotic Bcl-2 and HSP47 in arterial repair
J. Am. Coll. Cardiol., September 3, 2003; 42(5): 930 - 938.
[Abstract] [Full Text] [PDF]


Home page
Obstet GynecolHome page
R. W. Powers, M. S. Dunbar, M. J. Gallaher, and J. M. Roberts
The 677 C-T Methylenetetrahydrofolate Reductase Mutation Does Not Predict Increased Maternal Homocysteine During Pregnancy
Obstet. Gynecol., April 1, 2003; 101(4): 762 - 766.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. A. J. Kluijtmans, I. S. Young, C. A. Boreham, L. Murray, D. McMaster, H. McNulty, J. J. Strain, J. McPartlin, J. M. Scott, and A. S. Whitehead
Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults
Blood, April 1, 2003; 101(7): 2483 - 2488.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
B. Keavney and H. Watkins
Evolution of genetic analysis strategies in coronary heart disease: a case of unnatural selection?
Eur. Heart J., February 2, 2001; 22(4): 271 - 273.
[PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.